<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lawler ME</submitter><funding>NCI NIH HHS</funding><pagination>5888-5901</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12666352</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(22)</volume><pubmed_abstract>&lt;h4>Abstract&lt;/h4>The consequences of activated innate immune signaling in acute myeloid leukemia (AML) is not well understood. Using ligands directed at the toll-like family receptors (TLR) in models of high-risk AML, we uncover that TLR2 ligands exert unique antileukemic effects that are distinct from other TLRs. Although TLR2 signaling broadly induces inflammatory gene expression in AML cells, at the single-cell level, cell-type-dependent, divergent transcriptional responses coordinate cellular outputs of proliferation, differentiation, cell death, and activation of immune cell function. TLR2 ligands were the only TLR agonists capable of extending survival of AML-bearing mice through leukemia stem cell (LSC) reprogramming that elevated major histocompatibility complex (MHC) class II surf</pubmed_abstract><journal>Blood advances</journal><pubmed_title>TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells.</pubmed_title><pmcid>PMC12666352</pmcid><funding_grant_id>F31 CA268843</funding_grant_id><funding_grant_id>P30 CA056036</funding_grant_id><funding_grant_id>R00 CA248460</funding_grant_id><funding_grant_id>R37 CA226433</funding_grant_id><funding_grant_id>R01 CA226432</funding_grant_id><funding_grant_id>T32 CA236736</funding_grant_id><pubmed_authors>Bowman MS</pubmed_authors><pubmed_authors>Romer-Seibert JS</pubmed_authors><pubmed_authors>Lawler ME</pubmed_authors><pubmed_authors>Meyer SE</pubmed_authors><pubmed_authors>Eischen CM</pubmed_authors><pubmed_authors>Bowman RL</pubmed_authors><pubmed_authors>Mitra R</pubmed_authors></additional><is_claimable>false</is_claimable><name>TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells.</name><description>&lt;h4>Abstract&lt;/h4>The consequences of activated innate immune signaling in acute myeloid leukemia (AML) is not well understood. Using ligands directed at the toll-like family receptors (TLR) in models of high-risk AML, we uncover that TLR2 ligands exert unique antileukemic effects that are distinct from other TLRs. Although TLR2 signaling broadly induces inflammatory gene expression in AML cells, at the single-cell level, cell-type-dependent, divergent transcriptional responses coordinate cellular outputs of proliferation, differentiation, cell death, and activation of immune cell function. TLR2 ligands were the only TLR agonists capable of extending survival of AML-bearing mice through leukemia stem cell (LSC) reprogramming that elevated major histocompatibility complex (MHC) class II surf</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-07-15T06:57:44.943Z</modification><creation>2026-06-30T03:34:43.103Z</creation></dates><accession>S-EPMC12666352</accession><cross_references><pubmed>40833891</pubmed><doi>10.1182/bloodadvances.2025017018</doi></cross_references></HashMap>